Treatment of neovascularization myopic with ranibizumab: 18‐month results

Abstract Purpose To evaluate the efficacy of intravitreal Ranibizumab as treatment for choroidal neovascularisation due to pathological myopia Methods A retrospective, non‐comparative study of 21 eyes treated with intravitreal injections of Ranibizumab. Ten eyes had been treated previously with photodynamic therapy and eleven received Ranibizumab as first therapy. After thorough ophtalmologic examination, fluorescein angiography (FAG) and optical coherence tomography (OCT) intraocular injection was practised, a new treatment was decided according to the subjective impression of the patient, visual acuity, presence or absence of metamorphopsia, biomicroscopy and OCT examination. Results Twenty one eyes from 17 patients were finally included. Patients were followed up for 18 months. The mean age at initial treatment was 55.71 years. Mean refractive error was ‐12.6 diopters. Regarding AGF all neovascular membranes were classical and sub or yuxtafoveal localised. At the end of the 18 months after treatment 16 eyes (76.19%) showed better visual acuity ranging from one or more lines on Snellen chart, 10 eyes(47.61%) improved two lines or more, 4 eyes(19%) did not show any changes and one eye(4.76%) worsened two lines. At 18 months the mean best‐corrected visual acuity (BCVA) improved from 0.28 to 0.50 (p= 0.001). The mean central macular thickness decreased Conclusion Ranibizumab may be a good therapeutic option as treatment for choroidal neovascularisation due to pathological myopia, it improved visual acuity and anatomical features, even in non‐responders to photodynamic therapy.